2001, Biosimilars and Drug Pricing

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2001

Biosimilars

Drug Pricing

Three strategies for managing loss of exclusivity successfully

pharmaphorum

FEBRUARY 18, 2021

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. “Patent losses could sink Allergan”. billion in 2004.14

Prescription Filling

Prescription Filling Drug Pricing Biosimilars Compounding

Preliminary Injunction Decision in Chambers of Commerce Case Provides First Insights Into Merits of Medicare Negotiations Cases

FDA Law Blog: Biosimilars

OCTOBER 4, 2023

By Faraz Siddiqui — Last week, a federal court in Ohio denied a preliminary injunction motion by four Chambers of Commerce in their lawsuit against the Medicare Drug Price Negotiation Program. Engler , a 2001 decision by the Sixth Circuit Court of Appeals.

Drug Pricing

Drug Pricing Pharmaceutical Manufacturing Immunity Immunization

Pharmacist Digest

Three strategies for managing loss of exclusivity successfully

Preliminary Injunction Decision in Chambers of Commerce Case Provides First Insights Into Merits of Medicare Negotiations Cases

Stay Connected